Finally, we showed that chronic intraperitoneal injection of the PDK1 inhibitor BX912 (5 mg per kg body weight per day; 0.25 μl h−1) starting at 130 days post infection delayed mortality (Fig. 3a), reduced the motor deficits associated with prion infection (Fig. 3b) and decreased the PrPSc level (Fig. 3c) with the same magnitude in mice infected with PrPSc inocula Aβ-free or not. This evidence concerns the gene PDK1 and infection.